- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03788759
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The underlying pathogenesis of schizophrenia remains unknown, but aberrant reduction-oxidation has gained increasing support as an hypothesis to help explain the pathophysiology of the disease. Alpha-lipoic acid (ALA) is a naturally occurring antioxidant, essential for the function of different enzymes of mitochondria's oxidative metabolism, that is currently approved to treat diabetic neuropathic pain9. ALA and its reduced form, dihydrolipoic acid (DHLA), have important advantages over other antioxidant agents such as vitamin E and C, partly due to their amphiphilic properties, which confer antioxidant actions in the membrane as well as in the cytosol. A preclinical study conducted in our lab showed that ALA alone and combined with clozapine reverses schizophrenia associated symptoms and pro-oxidant changes induced by ketamine in mice. Before the widespread use of antipsychotics, two studies found that low doses of ALA relieved symptoms in patients with schizophrenia.
More recently, my colleagues and I conducted an open label proof of concept study that provided encouraging evidence that low doses of ALA might be an effective adjunctive treatment for schizophrenia. Based on promising preliminary results, the investigators will now test ALA in a more rigorous placebo-controlled clinical study.
Specific Aim1: To conduct a prospective, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adjuvant treatment with low doses (100mg) of ALA to treat cognitive and negative symptoms of patients with schizophrenia. The investigators will randomize 50 patients over 4 months.
Specific Aim 2: To quantify changes in biomarkers of oxidative stress in response to adjunctive treatment with ALA. The hypothesis is that changes in these biomarkers will mediate the clinical response to ALA.
Research Plan: To carry out a proof of concept 4-month prospective, randomized, double-blind, controlled trial of alpha-lipoic acid, at doses of 100 mg/day or identical placebo tablets, added to ongoing antipsychotics in 50 stable patients (ages 18-60 years, 25 patients per group) with diagnosis of schizophrenia. The study will be conducted at the Drug Research and Development Center (NPDM), at the Universidade Federal do Ceará, Fortaleza, Brazil. This center has a long history of performing placebocontrolled trials in clinical medicine (http://www.npdm.ufc.br/) and has the necessary infrastructure to successfully complete the proposed study protocol. All participants will give written informed consent prior to study enrollment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
CE
-
Fortaleza, CE, Brazil, 60430-275
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos - UFC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capacity to provide informed consent;
- Schizophrenia diagnosis (made by research psychiatrists using the Structured Clinical Interview, SCID-5, for Diagnostic and Statistical Manual of Mental Disorders);
- Negative and/or cognitive symptoms despite adequate antipsychotic treatment;
- Ages 18-60 years
Exclusion Criteria:
- 6-month history of any drug or alcohol abuse or dependence;
- Changes in psychotropic medications within the last 4 weeks;
- Actual valproate use (potential interaction with ALA);
- General medical illness including autoimmune disorders, known chronic infections such as HIV or hepatitis C, and liver or renal failure that could adversely impact on patient outcome;
- Women who are planning to become pregnant, are pregnant, or are breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
25 subjects will be randomized to 100mg of alpha-lipoic acid.
|
Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
|
Placebo Comparator: Placebo group
25 subjects will be randomized to placebo.
|
Administration of placebo, as an adjunct to antipsychotic medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Brief Psychiatry Rating Scale (BPRS) scores
Time Frame: Baseline and 16 weeks
|
18-item rating scale to assess changes in psychopathology; each item is scored 0-6, yielding a total between 0 and 108.
|
Baseline and 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Simpson-Angus Extrapyramidal Symptoms Scale (SAS) scores
Time Frame: Baseline and 16 weeks
|
10-item rating scale to assess extrapyramidal symptoms; each item is scored 0-4, yielding a total between 0 and 40.
|
Baseline and 16 weeks
|
Brain resting state activity
Time Frame: Baseline and 16 weeks
|
Functional Magnetic Resonance Imaging (fMRI) scans before and after treatment
|
Baseline and 16 weeks
|
Gut Microbiota Composition
Time Frame: Baseline and 16 weeks
|
Analyses of patient's gut microbiota
|
Baseline and 16 weeks
|
Change in Body Mass Index (BMI)
Time Frame: Baseline and 16 weeks
|
Weight and height will be combined to report BMI in kg/m^2
|
Baseline and 16 weeks
|
Change in Abdominal Circumference
Time Frame: Baseline and 16 weeks
|
Abdominal Circumference in cm
|
Baseline and 16 weeks
|
Change in plasma Aspartate Aminotransferase (AST)
Time Frame: Baseline and 16 weeks
|
AST in U/L
|
Baseline and 16 weeks
|
Change in plasma Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT)
Time Frame: Baseline and 16 weeks
|
ALT in U/L
|
Baseline and 16 weeks
|
Change in Hemoglobin concentration (HC)
Time Frame: Baseline and 16 weeks
|
HC in g/dL
|
Baseline and 16 weeks
|
Change in Hematocrit (Ht)
Time Frame: Baseline and 16 weeks
|
Ht in %
|
Baseline and 16 weeks
|
Change in White blood cell count (WBC)
Time Frame: Baseline and 16 weeks
|
WBC in number per microliter
|
Baseline and 16 weeks
|
Change in Neutrophil Count (NC)
Time Frame: Baseline and 16 weeks
|
NC in number per microliter
|
Baseline and 16 weeks
|
Change in Platelet Count (PC)
Time Frame: Baseline and 16 weeks
|
PC in number per microliter
|
Baseline and 16 weeks
|
Change in Glycohemoglobin (HbA1c)
Time Frame: Baseline and 16 weeks
|
HbA1c in %
|
Baseline and 16 weeks
|
Change in serum level of Vitamin B12
Time Frame: Baseline and 16 weeks
|
Vitamin B12 in pg/mL
|
Baseline and 16 weeks
|
Change in serum level of Folic Acid
Time Frame: Baseline and 16 weeks
|
Folic Acid in ng/mL
|
Baseline and 16 weeks
|
Change in Plasma Glutathione (GSH)
Time Frame: Baseline and 16 weeks
|
GSH in ng/mL
|
Baseline and 16 weeks
|
Change in serum level of Nitrite
Time Frame: Baseline and 16 weeks
|
Nitrite in nanomole/mililiter
|
Baseline and 16 weeks
|
Change in serum level of Thiobarbituric acid reactive substances (TBARS)
Time Frame: Baseline and 16 weeks
|
TBARS in mmol of malonaldehyde/mL
|
Baseline and 16 weeks
|
Change in serum level of Interleukin 1 β (IL-1β)
Time Frame: Baseline and 16 weeks
|
IL-1β in pg/mL
|
Baseline and 16 weeks
|
Change in serum level of Interleukin-4
Time Frame: Baseline and 16 weeks
|
IL-4 in pg/mL
|
Baseline and 16 weeks
|
Change in serum level of Interferon gamma (IFNγ)
Time Frame: Baseline and 16 weeks
|
IFNγ in pg/mL
|
Baseline and 16 weeks
|
Change in serum level of Tumor necrosis factor alpha (TNF-α)
Time Frame: Baseline and 16 weeks
|
TNF-α in pg/mL
|
Baseline and 16 weeks
|
Change in Indoleamine 2,3-dioxygenase (IDO) enzymatic activity
Time Frame: Baseline and 16 weeks
|
IDO activity in U IDO mol^-1/mg^-1
|
Baseline and 16 weeks
|
Change in serum level of Eotaxin
Time Frame: Baseline and 16 weeks
|
Eotaxin in ng/mL
|
Baseline and 16 weeks
|
Change in serum level of Isoprostanes
Time Frame: Baseline and 16 weeks
|
Isoprostanes in pg/mL
|
Baseline and 16 weeks
|
Change in serum level of Calprotectin
Time Frame: Baseline and 16 weeks
|
Serum Calprotectin in ng/mL
|
Baseline and 16 weeks
|
Change in serum level of Serotonin
Time Frame: Baseline and 16 weeks
|
Serotonin in ng/mL
|
Baseline and 16 weeks
|
Change in Block Corsi Test
Time Frame: Baseline and 16 weeks
|
This test assesses visuo-spatial short term working memory.
Participants are asked to mimick a researcher as he/she taps a sequence of up to nine identical spatially separated blocks.
The test measures both the number of correct sequences and the longest sequence remembered.
|
Baseline and 16 weeks
|
Change in serum level of Tryptophan
Time Frame: Baseline and 16 weeks
|
Tryptophan in micrograms/mL
|
Baseline and 16 weeks
|
Change in Trail Making Test
Time Frame: Baseline and 16 weeks
|
Trail Making Test measured in time and number of errors.
It tests visual attention and task switching.
It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
Provide information about visual search speed, scanning, speed of processing, mental flexibility, executive functioning.
|
Baseline and 16 weeks
|
Change in Subtest Digit Span
Time Frame: Baseline and 16 weeks
|
Individual tries to repeat digits forward, backward, and in ascending order.
This test measures short term memory, working memory.
The score is the maximum number of digits correctly remembered.
|
Baseline and 16 weeks
|
Category (Animal) Fluency
Time Frame: Baseline and 16 weeks
|
Participants have to produce as many words as possible from a category in a given time (usually 60 seconds).
Performance measure is the total number of words
|
Baseline and 16 weeks
|
F-A-S test
Time Frame: Baseline and 16 weeks
|
It assesses phonemic fluency by requesting an individual to orally produce as many words as possible that begin with the letters F, A, and S within a prescribed time frame, usually 1 min.
|
Baseline and 16 weeks
|
Rey Auditory Verbal Learning Test
Time Frame: Baseline and 16 weeks
|
Participants are asked to repeat list of 15 unrelated words; another list of 15 unrelated words are given and participants must again repeat the original list of 15 words and then again after 30 minutes.
Score range: 0-15
|
Baseline and 16 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lia LO Sanders, MD, PhD, Núcleo de Pesquisa e Desenvolvimento de Medicamentos
Publications and helpful links
General Publications
- Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011 Jan;35(3):878-93. doi: 10.1016/j.neubiorev.2010.10.008. Epub 2010 Oct 23.
- Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T, Harkanen T, Koskinen S, Lonnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007 Jan;64(1):19-28. doi: 10.1001/archpsyc.64.1.19.
- Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014 May;24(5):693-709. doi: 10.1016/j.euroneuro.2013.10.017. Epub 2013 Nov 11.
- Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids. 1996 Aug;55(1-2):33-43. doi: 10.1016/s0952-3278(96)90143-x.
- Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, Polari A, Steullet P, Preisig M, Teichmann T, Cuenod M, Do KQ. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011 Oct 1;15(7):2003-10. doi: 10.1089/ars.2010.3463. Epub 2010 Oct 30.
- Fournier M, Ferrari C, Baumann PS, Polari A, Monin A, Bellier-Teichmann T, Wulff J, Pappan KL, Cuenod M, Conus P, Do KQ. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull. 2014 Sep;40(5):973-83. doi: 10.1093/schbul/sbu053. Epub 2014 Mar 31.
- Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004 Jul;9(7):684-97, 643. doi: 10.1038/sj.mp.4001511.
- Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud. 2009 Winter;6(4):230-6. doi: 10.1900/RDS.2009.6.230. Epub 2009 Dec 30.
- Scott BC, Aruoma OI, Evans PJ, O'Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res. 1994 Feb;20(2):119-33. doi: 10.3109/10715769409147509.
- Vasconcelos GS, Ximenes NC, de Sousa CN, Oliveira Tde Q, Lima LL, de Lucena DF, Gama CS, Macedo D, Vasconcelos SM. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. Schizophr Res. 2015 Jul;165(2-3):163-70. doi: 10.1016/j.schres.2015.04.017. Epub 2015 Apr 30.
- GIAMATTEI L. [Thioctic acid in therapy of schizophrenia]. Osp Psichiatr. 1957 Apr-Jun;25(2):221-8. No abstract available. Italian.
- ALTSCHULE MD, GONCZ RM, HOLLIDAY PD. Carbohydrate metabolism in brain disease. XI. Effects of thioctic (alpha-lipoic) acid in chronic schizophrenia. AMA Arch Intern Med. 1959 May;103(5):726-9. doi: 10.1001/archinte.1959.00270050048008. No abstract available.
- Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, van Rensburg SJ, Harvey BH. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014 Sep;158(1-3):230-5. doi: 10.1016/j.schres.2014.06.004. Epub 2014 Jul 2.
- Kim E, Park DW, Choi SH, Kim JJ, Cho HS. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J Clin Psychopharmacol. 2008 Apr;28(2):138-46. doi: 10.1097/JCP.0b013e31816777f7.
- Seybolt SE. Less is more. Schizophr Res. 2014 Dec;160(1-3):222-3. doi: 10.1016/j.schres.2014.10.022. Epub 2014 Oct 31. No abstract available.
- Sanders LLO, de Souza Menezes CE, Chaves Filho AJM, de Almeida Viana G, Fechine FV, Rodrigues de Queiroz MG, Goncalvez da Cruz Fonseca S, Mendes Vasconcelos SM, Amaral de Moraes ME, Gama CS, Seybolt S, de Moura Campos E, Macedo D, Freitas de Lucena D. alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial. J Clin Psychopharmacol. 2017 Dec;37(6):697-701. doi: 10.1097/JCP.0000000000000800.
- Steibliene V, Bunevicius A, Savickas A, Prange AJ Jr, Nemeroff CB, Bunevicius R. Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. J Psychiatr Res. 2016 Feb;73:9-16. doi: 10.1016/j.jpsychires.2015.11.007. Epub 2015 Dec 1.
- Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S. Evidence that alpha-lipoic acid inhibits NF-kappaB activation independent of its antioxidant function. Inflamm Res. 2011 Mar;60(3):219-25. doi: 10.1007/s00011-010-0256-7. Epub 2010 Oct 7.
- Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343-8. doi: 10.1161/01.CIR.0000153272.48711.B9. Epub 2005 Jan 17.
- Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M. Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia. Mol Neurobiol. 2018 Jun;55(6):5184-5201. doi: 10.1007/s12035-017-0751-8. Epub 2017 Sep 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LipoicStudy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Alpha-lipoic acid
-
InVasc Therapeutics, Inc.CompletedHypertension | DiabetesUnited States
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan
-
Rebecca SpainCompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisProgressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Heba Allah Ali Abd El-Halim MabroukTanta UniversityUnknown
-
Seoul St. Mary's HospitalGlaxoSmithKlineTerminatedNASH (Non-alcoholic Steato-hepatitis)
-
Augusta UniversityXinjiang Medical UniversityCompletedObesity | Cardiovascular Disease | Type 2 DiabetesChina
-
University Health Network, TorontoCanadian Diabetes AssociationCompletedType 2 Diabetes | PrediabetesCanada
-
Oregon State UniversityOregon Health and Science University; National Center for Complementary and...Active, not recruiting
-
University of British ColumbiaRecruitingObstructive Sleep Apnea of AdultCanada